Full-Time

Key Account & Access Manager

Confirmed live in the last 24 hours

Blueprint Medicines

Blueprint Medicines

501-1,000 employees

No salary listed

Senior

Italy

The position is field-based and covers either the territory of Italy North-West or North-East based on the candidate’s place of living.

Category
Strategic Account Management
Sales & Account Management
Required Skills
Sales
Data Analysis
Requirements
  • Bachelor’s or master’s degree in scientific disciplines and/or any title defined by the Italian law that allows to qualify as Scientific Representative
  • 4-7 years of pharmaceutical industry experience working in Sales.
Responsibilities
  • Responsible for driving and achieving the business objectives of new product launches and in market assets.
  • Identify key external stakeholders and develop deep understanding of their needs, collaborating on initiatives and co-creating mutually beneficial solutions that will add value to them and the patients.
  • Support and advise Healthcare professionals on the correct use of Blueprint Medicines product and services portfolio with effective scientific and product communication.
  • Drive account stakeholder relationships; develop and monitor long-term relationships between Blueprint Medicines, the account, and its key stakeholders.
  • Execute local market access plans at regional and hospital level, working in strict relationship with the Market Access Team.
  • Design strategy for and be accountable for key accounts, develop and execute concrete action plans for those.
  • Implement programs to support the journey of patients and ultimately work with the local health care system to improve the treatment of this disease and/or the patient journey.
  • Follow up relevant matters concerning delivery, tenders, cash collection and all the administrative tasks related to the local access and order fulfillment.
  • Lead and develop local strategic customer relationships and bring product to launch within compliance and legal requirements.
  • Develop and execute projects initiated by relevant team members to support their customers, resulting in better and more efficient treatment outcomes helping Blueprint Medicines to be a key partner in the product area by stakeholders.
  • Proactively share insights and best practices within Italian team and within INT region.
  • Proactively coordinate collaboration with medical affairs and market access (and other internal stakeholders) to ensure alignment in objectives and activities with accounts and external stakeholders.
  • Monitor the account plan progress and hold self-accountable for the prioritized plans execution.
  • Lead the core account team meetings and present account plans and progress at relevant local meetings with management.
  • Prioritize and manage accounts by assessing appropriate business opportunities through contacts with key decision-makers and important local stakeholders.
  • Systematically analyze success of plans (e.g., sales, market developments, competitors) and propose mitigating actions as needed.
Desired Qualifications
  • Experience in field market access preferred but not necessary.
  • Experience in managing customer relationships across the full spectrum of customer types in healthcare industry.
  • Account management experience desirable and knowledge in therapy and product area.
  • A very strong sense of urgency to address key stakeholder needs.
  • Knowledge in National and Regional Healthcare system and the local and therapy specific policies that impact decision making.
  • Strategic Approach, balancing between driving the short-term goals and the long-term vision.
  • Strong collaboration skills. Establish empathic and productive relationships and partnerships with others across the organization to ensure common understanding of objectives and achievement of shared goals.
  • Drive for results, holding self and others accountable for delivering on commitments that align with our short- and long-term goals, never forgetting the result is to help patients through innovation in medicine.
  • Proactive networking to influence the commercial strategy by supporting processes, relationships, and efficiencies in areas of accountability.
  • High energy and creative problem-solving mindset and skills.
  • Good presentation skills and English command, both written and oral.
  • Specialty medicines or rare disease experience, preferred.
  • Demonstrated self-starter and team player with strong interpersonal, presentation and communication skills.
  • Demonstrated ability to work collaboratively in a dynamic, team-oriented environment.
  • Empathic, positive, solutions-oriented mindset, active listening capability required.
  • Adept, nimble, energetic, and comfortable in a fast-paced, dynamic, and collaborative environment.
  • Capable of taking a hands-on approach and willing to “roll up one’s sleeves” and make do with the available.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2011

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for targeted therapies boosts Blueprint Medicines' market potential.
  • FDA initiatives expedite approval for Blueprint's innovative systemic mastocytosis treatments.
  • Increasing systemic mastocytosis prevalence aligns with Blueprint's therapeutic focus.

What critics are saying

  • Competition from Deciphera Pharmaceuticals' KIT inhibitor, ripretinib, poses a market threat.
  • Stringent European regulations may hinder Blueprint's market expansion.
  • Potential patent expirations could lead to generic competition and revenue loss.

What makes Blueprint Medicines unique

  • Blueprint Medicines leads in mast cell-targeted therapies with AYVAKIT and BLU-808.
  • AYVAKIT shows long-term efficacy and safety in treating indolent systemic mastocytosis.
  • BLU-808 offers a wide therapeutic window as a first-in-class oral KIT inhibitor.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Commuter Benefits

Mental Health Support

Employee Stock Purchase Plan

Parental Leave

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
ETF Daily News
Mar 8th, 2025
Proficio Capital Partners LLC Makes New $1.01 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC)

Proficio Capital Partners LLC makes new $1.01 million investment in Blueprint Medicines Co. (NASDAQ:BPMC).

Defense World
Mar 7th, 2025
Truist Financial Corp Makes New Investment in Blueprint Medicines Co. (NASDAQ:BPMC)

Truist Financial Corp makes new investment in Blueprint Medicines Co. (NASDAQ:BPMC).

Medical Update Online
Mar 4th, 2025
Blueprint Medicines highlights 'decade of leadership' in Mast Cell research with new AYVAKIT and BLU-808 data at AAAAI/WAO 2025

Blueprint Medicines highlights 'decade of leadership' in Mast Cell research with new AYVAKIT and BLU-808 data at AAAAI/WAO 2025.

PR Newswire
Feb 28th, 2025
Blueprint Medicines Highlights Leading Portfolio Of Mast Cell-Targeted Therapies At 2025 Aaaai / Wao Joint Congress

-- Updated data show AYVAKIT® (avapritinib) was safe and effective for long-term treatment of ISM, with sustained symptom and quality-of-life benefit and no new safety signals with multiple years of therapy ---- AYVAKIT-treated patients achieved improvements in bone health based on an analysis of bone mineral density scans, underscoring the importance of treating patients early in the ISM disease course ---- BLU-808 healthy volunteer trial results demonstrate wide therapeutic window for modulating mast cell activity, affirming potential as best- and first-in-class oral wild-type KIT inhibitor --CAMBRIDGE, Mass., Feb. 28, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting its ongoing efforts to innovate the treatment of mast cell-driven diseases. The presentations include three-year median follow-up data from the registrational PIONEER trial demonstrating the strong long-term efficacy and safety of AYVAKIT® (avapritinib) in patients with indolent systemic mastocytosis (ISM), and real-world evidence further characterizing the substantial burden of the disease, highlighting the urgency to treat. In addition, the company will report positive data from the Phase 1 healthy volunteer trial evaluating BLU-808, an investigational, highly potent and selective oral inhibitor of wild-type KIT, consistent with top-line data previously announced in January 2025. A total of 14 data presentations, including two oral presentations, will be reported at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) Joint Congress being held February 28-March 3 in San Diego."We are incredibly proud to showcase our mast cell therapy portfolio at AAAAI / WAO, with 14 presentations highlighting more than a decade of leadership and collaboration with the mast cell disease community, including renowned medical institutions pioneering innovative research and multi-disciplinary patient care," said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines. "In ISM, new data have reinforced that AYVAKIT was very well-tolerated after multiple years of treatment, with a low discontinuation rate and safety results that have remained consistent with the safety profile from the placebo-controlled study as summarized in the FDA-approval label

Defense World
Feb 17th, 2025
Blueprint Medicines Corporation Reports Strong Financial Results for 2024

Furthermore, Blueprint Medicines announced the appointment of Sherwin Sattarzadeh as Chief Business Officer, succeeding Helen Ho.